NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...

Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across ...

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders for ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after ...

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and ...